EUVIMEDEUVIMED entdecken
Open Access

Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia

Lindsey A Kuchenbecker iD, Philip W Tipton iD, Yuka Martens, Matthew R Brier iD, Nihal Satyadev iD, S Richard Dunham iD, Evelyn B Lazar, Maxwell V Dacquel, Rachel L Henson, Guojun Bu, Michael D Geschwind, John C Morris und 4 weitere

Annals of Neurology · 2024-02 · 95 (2) · 299-313

DOI: 10.1002/ana.26822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 10.11.2023. Verfasst von Lindsey A Kuchenbecker und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Neurodegenerative Diseases, Dementia. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NINDS NIH HHS, National Institute on Aging.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study was undertaken to apply established and emerging cerebrospinal fluid (CSF) biomarkers to improve diagnostic accuracy in patients with rapidly progressive dementia (RPD). Overlap in clinical presentation and results of diagnostic tests confounds etiologic diagnosis in patients with RPD. Objective measures are needed to improve diagnostic accuracy and to recognize patients with potentially treatment‐responsive causes of RPD.

Methods

Biomarkers of Alzheimer disease neuropathology (amyloid‐β 42/40 ratio, phosphorylated tau [p‐tau181, p‐tau231]), neuroaxonal/neuronal injury (neurofilament light chain [NfL], visinin‐like protein‐1 [VILIP‐1], total tau), neuroinflammation (chitinase‐3‐like protein [YKL‐40], soluble triggering receptor expressed on myeloid cells 2 [sTREM2], glial fibrillary acidic protein [GFAP], monocyte chemoattractant protein‐1 [MCP‐1]), and synaptic dysfunction (synaptosomal‐associated protein 25kDa, neurogranin) were measured in CSF obtained at presentation from 78 prospectively accrued patients with RPD due to neurodegenerative, vascular, and autoimmune/inflammatory diseases; 35 age‐ and sex‐matched patients with typically progressive neurodegenerative disease; and 72 cognitively normal controls. Biomarker levels were compared across etiologic diagnoses, by potential treatment responsiveness, and between patients with typical and rapidly progressive presentations of neurodegenerative disease.

Results

Alzheimer disease biomarkers were associated with neurodegenerative causes of RPD. High NfL, sTREM2, and YKL‐40 and low VILIP‐1 identified patients with autoimmune/inflammatory diseases. MCP‐1 levels were highest in patients with vascular causes of RPD. A multivariate model including GFAP, MCP‐1, p‐tau181, and sTREM2 identified the 44 patients with treatment‐responsive causes of RPD with 89% accuracy. Minimal differences were observed between typical and rapidly progressive presentations of neurodegenerative disease.

Interpretation

Selected CSF biomarkers at presentation were associated with etiologic diagnoses and treatment responsiveness in patients with heterogeneous causes of RPD. The ability of cross‐sectional biomarkers to inform upon mechanisms that drive rapidly progressive neurodegenerative disease is less clear. ANN NEUROL 2024;95:299–313

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeurodegenerative DiseasesDementiaHumansChitinase-3-Like Protein 1tau ProteinsCross-Sectional StudiesAmyloid beta-PeptidesBiomarkers

Substanzen

Chitinase-3-Like Protein 1tau ProteinsAmyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • Department of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.
  • Department of Neurology, Mayo Clinic Florida, Jacksonville, FL, USA.
  • Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
  • Hackensack Meridian JFK University Medical Center, Edison, NJ, USA.
  • Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.

ORCID-Profile: Lindsey A Kuchenbecker, Philip W Tipton, Matthew R Brier, Nihal Satyadev, S Richard Dunham, Gregory S Day

Förderung

  • NIA NIH HHS
  • NINDS NIH HHS
  • National Institute on Aging

Zitieren

APA

Kuchenbecker, L. A., Tipton, P. W., Martens, Y., Brier, M. R., Satyadev, N., Dunham, S. R., Lazar, E. B., Dacquel, M. V., Henson, R. L., Bu, G., Geschwind, M. D., Morris, J. C., Schindler, S. E., Herries, E., Graff-Radford, N. R., & Day, G. S. (2024). Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia. Annals of Neurology, 95(2), 299-313. https://doi.org/10.1002/ana.26822

Vancouver

Kuchenbecker LA, Tipton PW, Martens Y, Brier MR, Satyadev N, Dunham SR, et al. Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia. Annals of Neurology. 2024;95(2):299-313. doi:10.1002/ana.26822

BibTeX
@article{Kuchenbecker2024,
  author = {Kuchenbecker, Lindsey A and Tipton, Philip W and Martens, Yuka and Brier, Matthew R and Satyadev, Nihal and Dunham, S Richard and Lazar, Evelyn B and Dacquel, Maxwell V and Henson, Rachel L and Bu, Guojun and Geschwind, Michael D and Morris, John C and Schindler, Suzanne E and Herries, Elizabeth and Graff-Radford, Neill R and Day, Gregory S},
  title = {Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia},
  journal = {Annals of Neurology},
  year = {2024},
  volume = {95},
  number = {2},
  pages = {299--313},
  doi = {10.1002/ana.26822}
}
Kostenlos starten →